HTC
AKTX

Haverford Trust Company’s Akari Therapeutics AKTX Stock Holding History

Haverford Trust Company’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-25
Closed -$13K – 332
2022
Q3 		$13K Buy
+25
New +$20.6K ﹤0.01% 333

Other funds holding AKTX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OFW
Omnia Family Wealth Aventura, Florida $373M AUM 25.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
BMCM
Bryn Mawr Capital Management Philadelphia, Pennsylvania $2.06B AUM 19.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Haverford Trust Company's AKTX Position: Q4 2022 in Review

Haverford Trust Company sold out of Akari Therapeutics (AKTX) in Q4 2022, closing a stake of 25 shares — an estimated $13K sold.

Haverford Trust Company first reported a position in AKTX in Q3 2022 and held it in 1 quarter. The position peaked at $13K in Q3 2022. 15 funds tracked by Wall St. Rank hold AKTX as of Q4 2022.

  • Haverford Trust Company reported no remaining Akari Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Haverford Trust Company sold 25 Akari Therapeutics shares in Q4 2022, an estimated $13K.
  • Haverford Trust Company first reported a position in Akari Therapeutics in Q3 2022 and held it in 1 quarter.
  • Haverford Trust Company's Akari Therapeutics position peaked at $13K in Q3 2022.
  • 15 funds tracked by Wall St. Rank held Akari Therapeutics as of Q4 2022.

Based on Haverford Trust Company's 13F filing for Q4 2022, filed 13 Feb 2023.